Why the study?
Clinical biomarker use requires standardized assays and established cutoffs, prompting evaluation of standardized cutoffs for urinary CCL14 to predict persistent severe AKI.
Does urinary CCL14 concentration predict the development of persistent severe AKI in adult ICU patients with established KDIGO stages 2-3 AKI?
Does urinary CCL14 concentration predict the development of persistent severe AKI in adult ICU patients with established KDIGO stages 2-3 AKI?
Standardized urinary CCL14 cutoffs of 1.3 and 13 ng/ml successfully identify ICU patients with established AKI who are at high risk for developing persistent severe AKI, RRT, or death.
Answers are grounded in this paper and cite their sources.
CCL14 thresholds may stratify persistent severe AKI risk in ICU patients; leaves open whether biomarker-directed care improves outcomes.
Key Points Using a standardized assay, we provide operating characteristics for two cutoffs for urinary C-C motif chemokine ligand 14 (CCL14) for the prediction of persistent severe AKI. A CCL14 cutoff of 1.3 ng/ml identifies 91% of patients who developed persistent severe AKI, need for RRT, or death, with a negative predictive value of 92%. In multivariable analyses, a CCL14 >13 ng/ml was associated with 10.4 adjusted odds for persistent severe AKI, need for RRT, or death ( P <0.001). Background Clinical use of biomarkers requires the development of standardized assays and establishment of cutoffs. Urinary C-C motif chemokine ligand 14 (CCL14) has been validated to predict persistent severe AKI in critically ill patients with established AKI. We now report on the performance of standardized cutoffs using a clinical assay. Methods A second aim of the multicenter RUBY Study was to establish two cutoffs for the prediction of persistent severe AKI (defined as KDIGO stage 3 AKI for at least 72 consecutive hours). Patients who received renal replacement therapy (RRT) or died before achieving 72 hours in stage 3 AKI were also considered to have reached the end point. Results A cutoff value for urinary CCL14 of 1.3 ng/ml was determined to achieve high sensitivity (91%; 95% CI, 84% to 96%), and 13 ng/ml achieved high specificity (93%; 95% CI, 89% to 96%). The cutoff of 1.3 ng/ml identifies the majority (91%) of patients who developed persistent severe AKI with a negative predictive value of 92%. The cutoff at 13 ng/ml had a positive predictive value of 72% (with a negative predictive value of 75%). In multivariable adjusted analyses, a CCL14 concentration between 1.3 and 13 ng/ml had an adjusted odds ratio (aOR) of 3.82 (95% CI, 1.73 to 9.12; P =0.001) for the development of persistent severe AKI compared with those with a CCL14 ≤1.3 ng/ml, whereas a CCL14 >13 ng/ml had an aOR of 10.4 (95% CI, 3.89 to 29.9; P <0.001). Conclusions Using a clinical assay, these standardized cutoffs (1.3 and 13 ng/ml) allow for the identification of patients at high risk for the development of persistent severe AKI. These results have immediate utility in helping to guide AKI patient care and may facilitate future clinical trials. Clinical Trial registry name and registration number: Identification and Validation of Biomarkers of Acute Kidney Injury Recovery, NCT01868724
No takes yet. Share an insight, caveat, or question.
Koyner et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: